Specialty Pharmacy

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.

Study quantifies global body composition changes in patients with hepatitis C.

Natural killer cells ‘trained’ to more effectively attack cancer cells in patients with AML.

Top news of the day from across the health care landscape.

With no current treatments for patients with aggressive MS, new study findings provide hope.

The combined use of radiation therapy and a neutrophil stimulant can increase anti-tumor immunity.

New insights into a gene with anti-cancer activity may grow options for cancer treatment.

Experimental hepatitis C medication treats genotypes 1 through 6.

Direct-acting antivirals may cause hepatitis B reactivation in patients with an HCV/HBV co-infection.

Study findings contribute to the development of personalized treatment approaches for young children with eczema.

A new report updates medical community on primary sclerosing cholangitis.

New study may have found a way to prevent the loss of physical strength in type 1 diabetes patients.

Top news of the day from across the health care landscape.

Enzyme found to promote immune suppression by blocking the activation of anti-tumor T cells.

Rebekah L. Hanson, PharmD, BCPS, BCACP, clinical pharmacist and assistant professor at the UIC College of Pharmacy, discusses the challenge of out-of-pocket spending and the impact on drug adherence.

Spending on specialty drugs for autoimmune conditions now account for 10% of drug expenses.

A nanoparticle delivery system may help manage autoimmune diseases, such as multiple sclerosis, leaving a temporary black mark on patients.

A 7-year study identified genetic pathways hijacked by cancer stem cells to promote tumor growth.

Device shows promise preventing cancer cells from migrating to other organs in the body.

Top news of the day from across the health care landscape.

Pharma has had little incentive to develop drugs for diseases such as malaria, which killed more than 400,000 people last year.

Stelara is the first biologic approved for Crohn’s disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses.

Effective clinical programs in specialty pharmacy encourage adherence and lead to superior treatment outcomes.

Shutting off a critical enzyme in lipid synthesis found to stifle tumor growth.

Funding of $24 million will support programs and studies that address HIV-infection and prevention among at-risk groups.

Top news of the day from across the health care landscape.

A potential mechanism for the early detection of gastric cancer may lead to better treatment and prognosis.

Kevin James, RPh, MBA, vice president of payer strategy at US Bioservices, discusses challenges for patients in accessing specialty medications.

Drug-carrying synthetic polymer could deliver treatment to lung cancer cells without harming healthy cells.

Positive data from a pair of clinical trials announced at the 25th European Academy of Dermatology and Venereology Congress show Dupixent (dupilumab) is an effective option for moderate-to-severe atopic dermatitis.